全文获取类型
收费全文 | 93828篇 |
免费 | 9081篇 |
国内免费 | 4721篇 |
专业分类
耳鼻咽喉 | 2143篇 |
儿科学 | 397篇 |
妇产科学 | 1720篇 |
基础医学 | 10890篇 |
口腔科学 | 3399篇 |
临床医学 | 6667篇 |
内科学 | 11950篇 |
皮肤病学 | 1997篇 |
神经病学 | 368篇 |
特种医学 | 4233篇 |
外国民族医学 | 122篇 |
外科学 | 13931篇 |
综合类 | 16327篇 |
现状与发展 | 23篇 |
预防医学 | 1973篇 |
眼科学 | 423篇 |
药学 | 5033篇 |
15篇 | |
中国医学 | 1148篇 |
肿瘤学 | 24871篇 |
出版年
2024年 | 137篇 |
2023年 | 1283篇 |
2022年 | 2482篇 |
2021年 | 3610篇 |
2020年 | 3128篇 |
2019年 | 2977篇 |
2018年 | 2836篇 |
2017年 | 3212篇 |
2016年 | 3622篇 |
2015年 | 4166篇 |
2014年 | 6126篇 |
2013年 | 5390篇 |
2012年 | 5545篇 |
2011年 | 6005篇 |
2010年 | 4814篇 |
2009年 | 4800篇 |
2008年 | 4988篇 |
2007年 | 5257篇 |
2006年 | 4919篇 |
2005年 | 4469篇 |
2004年 | 3561篇 |
2003年 | 3131篇 |
2002年 | 2644篇 |
2001年 | 2529篇 |
2000年 | 2145篇 |
1999年 | 1743篇 |
1998年 | 1581篇 |
1997年 | 1424篇 |
1996年 | 1262篇 |
1995年 | 1107篇 |
1994年 | 1001篇 |
1993年 | 703篇 |
1992年 | 629篇 |
1991年 | 554篇 |
1990年 | 473篇 |
1989年 | 423篇 |
1988年 | 409篇 |
1987年 | 345篇 |
1986年 | 272篇 |
1985年 | 321篇 |
1984年 | 272篇 |
1983年 | 195篇 |
1982年 | 211篇 |
1981年 | 210篇 |
1980年 | 195篇 |
1979年 | 153篇 |
1978年 | 112篇 |
1977年 | 79篇 |
1976年 | 61篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
《European journal of surgical oncology》2019,45(11):2090-2095
BackgroundWe sought to identify treatment disparities existing prior to publication of the 2015 American Thyroid Association Management Guidelines in order to identify patients with papillary thyroid cancer (PTC) at risk for receiving inadequate treatment.MethodsPatients diagnosed with PTC from 2011 to 2013 were identified using Surveillance, Epidemiology and End Results database. High-risk disease was defined as T4, N1, or M1. Chi-square tests compared characteristics of patients with and without high-risk disease and characteristics of high-risk patients who did and did not receive radioactive iodine ablation (RAI). Likelihoods of having high-risk disease, of receiving RAI, and of cause-specific death were calculated using regression analyses.ResultsSample included 32,229 individuals; 7894 (24.5%) had high-risk disease. Mean age was 50.0 years, 24,815 (77.0%) were female, and 21,318 (66.2%) were white. Odds of high-risk disease were greater among males (OR:2.04; 95% CI:1.92–2.16), Hispanics (OR:1.67; 95% CI:1.56–1.79) and Asians (OR:1.49; 95% CI:1.37–1.62), and uninsured (OR:1.24; 95% CI:1.07–1.43), and lower among patients ages 45–64 (OR:0.57; 95% CI:0.53–0.60), and ≥65 years (OR:0.54; 95% CI:0.50–0.59), and Blacks (OR:0.46; 95% CI:0.40–0.53). Most (69.3%) high-risk patients received RAI. Odds of receiving RAI were lower among patients age ≥65 years (OR:0.67; 95% CI:0.58–0.77), uninsured (OR:0.52; 95% CI:0.41–0.67), or with Medicaid (OR:0.58; 95% CI:0.50–0.69). RAI use reduced the risk of cause-specific mortality (HR:0.29; 95% CI:0.18–0.47).ConclusionKnowledge of these treatment disparities will allow recognition of groups at risk for high-risk disease and receiving inadequate treatment. 相似文献
83.
84.
85.
Background and aimPatient decision aids for oncological treatment options, provide information on the effect on recurrence rates and/or survival benefit, and on side-effects and/or burden of different treatment options. However, often uncertainty exists around the probability estimates for recurrence/survival and side-effects which is too relevant to be ignored. Evidence is lacking on the best way to communicate these uncertainties. The aim of this study is to develop a method to incorporate uncertainties in a patient decision aid for breast cancer patients to support their decision on radiotherapy.MethodsFirstly, qualitative interviews were held with patients and health care professionals. Secondly, in the development phase, thinking aloud sessions were organized with four patients and 12 health care professionals, individual and group-wise.ResultsConsensus was reached on a pictograph illustrating the whole range of uncertainty for local recurrence risks, in combination with textual explanation that a more exact personalized risk would be given by their own physician. The pictograph consisted of 100 female icons in a 10 x 10 array. Icons with a stepwise gradient color indicated the uncertainty margin. The prevalence and severity of possible side-effects were explained using verbal labels.ConclusionsWe developed a novel way of visualizing uncertainties in recurrence rates in a patient decision aid. The effect of this way of communicating risk uncertainty is currently being tested in the BRASA study (NCT03375801). 相似文献
86.
87.
Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma
下载免费PDF全文
![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Georgia Levidou Dimitrios Theodorou Nikolaos V. Michalopoulos Efstratios Patsouris Angelica A. Saetta 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(8):639-647
Among the numerous signaling pathways involved in tumorigenesis, PI3K‐AKT‐mTOR is a key one that regulates diverse cellular functions. However, its prognostic value in esophageal carcinoma remains unclear. In our study, we examined the immunohistochemical expression of phosphorylated (p‐) AKT, mTOR, p70S6K and 4E‐BP1 along with the mutational status of PIK3CA and AKT1 genes by High Resolution Melting Analysis and Pyrosequencing in 44 esophageal carcinomas. The results were correlated with the clinicopathological characteristics of the patients in an effort to define their possible prognostic significance. Total p‐mTOR cytoplasmic expression, assessed in 10 random areas, was positively correlated with tumor stage (Kruskal–Wallis ANOVA, I/II vs III/IV, p = 0.0500). Μoreover, maximum p‐mTOR cytoplasmic immunoexpression, estimated in hot spot areas, was positively associated with tumor grade (Mann–Whitney U test, I/II vs III, p = 0.0565). Interestingly, p‐4E‐BP1 immunoreactivity was negatively correlated with tumor histological grade (Mann–Whitney U test, I/II vs III, p = 0.0427). No mutation was observed in exons 9 and 20 of PIK3CA gene and in exon 4 of AKT1 gene. In conclusion, our findings depict the presence of activated PI3K/AKT/mTOR pathway in esophageal cancer bringing forward p‐mTOR and p‐4E‐BP1 for their potential role in esophageal carcinogenesis. Additional studies are warranted to validate our findings. 相似文献
88.
《Surgical pathology clinics》2015,8(4):587-621
According to the current World Health Organization (WHO), renal cell carcinomas (RCCs) that primarily affect adults are classified into 8 major subtypes. Additional emerging entities in renal neoplasia have also been recently recognized and these are discussed in further detail by Mehra et al (Emerging Entities in Renal Neoplasia, Surgical Pathology Clinics, 2015, Volume 8, Issue 4). In most cases, the diagnosis of a RCC subtype can be based on morphologic criteria, but in some circumstances the use of ancillary studies can aid in the diagnosis. This review discusses the morphologic, genetic, and molecular findings in RCCs previously recognized by the WHO, and provides clues to distinction from each other and some of the newer subtypes of RCC. As prognosis and therapeutic options vary for the different subtypes of RCC, accurate pathologic distinction is critical for patient care. 相似文献
89.
Zhengxian Huang Nan Xie Haichao Liu Yuehan Wan Yue Zhu Ming Zhang Yifan Tao Han Zhou Xiqiang Liu Jinsong Hou Cheng Wang 《Journal of oral pathology & medicine》2019,48(9):788-798
It has been suggested that tumour‐infiltrating lymphocytes (TILs) are associated with the progression of oral squamous cell carcinoma (OSCC). However, the prognostic value of TILs is inconclusive due to the heterogeneity of immune cells within the tumour microenvironment. In this meta‐analysis, we aimed to assess the prognostic value of TILs in OSCC. The PubMed, Cochrane, Embase, Scopus and Web of Science databases were searched up to April 20, 2019, and 33 studies were ultimately included in this meta‐analysis. Our pooled meta‐analysis showed that high infiltration of CD8+ TILs, CD45RO+ TILs and CD57+ TILs favoured better overall survival (OS). However, high infiltration of CD68+ macrophages and CD163+ macrophages was associated with poor prognosis in OSCC. These findings suggest that CD8+ TILs, CD45RO+ TILs, CD57+ TILs, CD68+ macrophages and CD163+ macrophages might serve as novel prognostic factors and therapeutic targets in OSCC. 相似文献
90.
皮肤鳞状细胞癌(cSCC)是角质形成细胞来源的恶性肿瘤之一。转录组是特定条件下细胞内全部转录产物的总和,包括编码mRNA和非编码RNA。研究发现,与正常细胞相比,鳞癌细胞在基因转录水平和模式上存在很大差异,具有不同转录表达谱。微小RNA(miRNA)可通过抑制转录产物的翻译,从而调控靶基因的表达,影响cSCC细胞的增殖、分化和凋亡等病理过程。越来越多的研究表明,miRNAs作为cSCC诊断、预测预后和治疗靶点的生物标志物,在临床上具有广阔的应用前景。本文通过回顾分析cSCC的miRNA表达谱,主要对其中经实验证实表达上调和下调的miRNAs在cSCC中的研究进展作一综述。 相似文献